Navigation Links
MicroConstants Expands Biomarker Testing and Analysis Services for Preclinical and Clinical Diagnostic Research

SAN DIEGO, June 25, 2013 /PRNewswire/ -- MicroConstants, a Contract Research Organization (CRO) specializing in regulated bioanalysis and DMPK, announces the appointment of Doinita Serban, Ph.D. as director of biomarker research to oversee the expansion of biomarker testing and analysis services for preclinical and clinical diagnostic research. Doinita's extensive experience with biomarker assay development, validation, and profiling of disease panels, coupled with the implementation of the Luminex platform, will enable MicroConstants to broaden their biomarker analysis capabilities to include additional assay formats, such as multiplex immunoassays, gene expression and profiling assays.

Doinita brings to MicroConstants more than 15 years of experience in the pharmaceutical industry specializing in cancer and vascular biology, immunology, and bioanalysis in preclinical and clinical research. She has spent over 10 years developing and validating biomarker assays for biopharmaceuticals on a variety of instrumentation platforms to support clinical diagnostic research for various therapeutic areas, including oncology, inflammation, infectious and vascular diseases.

"Although multiplex biomarker assays are a new service offering for MicroConstants, Doinita's in-depth knowledge of biomarker analysis and pharmacodynamic targets will be a valuable asset to the department as we expand our capabilities," says David F. Beyerlein, vice president of global operations at MicroConstants. "These biomarker assays will provide our pharmaceutical and biotech clients with valuable insight into the efficacy of therapies for cancer and other complex diseases to help guide their decisions throughout all phases of drug development."

There is an urgent need for the discovery of biomarkers that can be used in blood-based, non-invasive molecular tests. These tests can be used to assist in the detection and diagnosis of diseases, to classify tissues and patients for clinical trials, and to monitor disease response to treatment and relapse. Furthermore, linking the molecular aberrations of diseases to drug responses can guide treatment choices and identify new therapeutic applications.

MicroConstants will use the Luminex platform to study the cellular fitness of engineered cells in response to a collection of drugs, enabling the systematic analysis of thousands of gene-drug interactions and unveiling of resistance mechanisms. The multiplex technology will also be used to perform both gene and protein expression assays. Custom assays can be created for genotyping and protein assessment (i.e. tyrosine kinases, growth factors etc.), and commercially available kits can be used to monitor cytokine levels.

About MicroConstants, Inc.

MicroConstants is a GLP-compliant Contract Research Organization (CRO) focused on performing regulated bioanalysis, drug metabolism and pharmacokinetic analysis to support discovery, preclinical and clinical drug development studies. They specialize in method development, method validation and sample analysis of small molecules, biopharmaceuticals, biomarkers and metabolites using LC/MS/MS, HPLC/UV, immunoassay and multiplex techniques. For more information, please visit

SOURCE MicroConstants
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroConstants China Signs Site Management Organization Agreement with the Clinical Research Center of No. 307 Hospital
2. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
3. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
4. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
5. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
6. S1 Biopharma Expands Focus to Include Male Sexual Health
7. PRA Expands Operations in Europe
8. USANA Health Sciences Expands Award-Winning Research and Development Team
9. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
10. Argus Expands Specialty Pharmacy with Amber Pharmacy Collaboration
11. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Endo International ... Rajiv De Silva , President and CEO, will discuss ... Healthcare Conference in New York on ... . Click on Investor Relations, and then the ... prior to the presentation,s start time to visit the site ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... ... , ... Today, Mothers Against Drunk Driving (MADD) learned that the ... the first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol ... National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
Breaking Medicine News(10 mins):